LAUSR

PURPOSE OF REVIEW New treatment options have been studied over the last several years, with a recent approval, a first for Behcet syndrome, in the United States. New management guidelines have also been published, helping with this nowadays more commonly recognized condition's management. The goal of this review is to summarize the most important and potentially clinically relevant recent developments and discuss their impact in the management of patients with Behcet syndrome. RECENT FINDINGS Apremilast is now approved for the treatment of oral ulcer of Behcet syndrome in the United States. It's possible benefits in controlling nonoral ulcer features of the syndrome are awaited. Long-term use of tumor necrosis factor inhibitors for the treatment of especially eye disease in Behcet syndrome seems to be safe and efficacious. New treatment options such as ustekinumab, secukinumab, tocilizumab and others have early promising data but more studies are needed to better clarify their role in Behcet management. SUMMARY The last 2 years have not only seen the approval of the first drug specifically labeled for the treatment of Behcet syndrome in the case of apremilast, many groups have also presented and published their findings on promising new therapeutic agents, which may soon be added to our tools in treating this condition. We also know more about other drugs, such as tumor necrosis factor inhibitors as many patients have been on these for long periods of time, and long-term follow-up data seem to confirm their role in Behcet treatment. Lack of placebo controlled, randomized trials, for the most part, are still outstanding issues.